An 89Zr-Labeled PSMA Tracer for PET/CT Imaging of Prostate Cancer Patients | Journal of Nuclear Medicine
An 89Zr-Labeled PSMA Tracer for PET/CT Imaging of Prostate Cancer Patients | Journal of Nuclear Medicine
Posts
Showing posts from March, 2022
A Comprehensive Assessment of 68Ga-PSMA-11 PET in Biochemically Recurrent Prostate Cancer: Results from a Prospective Multicenter Study on 2,005 Patients | Journal of Nuclear Medicine
- Get link
- X
- Other Apps
Inherited risk assessment and its clinical utility for predicting prostate cancer from diagnostic prostate biopsies | Prostate Cancer and Prostatic Diseases
- Get link
- X
- Other Apps
Inherited risk assessment and its clinical utility for predicting prostate cancer from diagnostic prostate biopsies | Prostate Cancer and Prostatic Diseases
- Get link
- X
- Other Apps
Rochester Institute of Technology Scientists Secure NIH Grant to Study Virus as Prostate Cancer Treatment
- Get link
- X
- Other Apps
A cancer stem cell population underlies a multi-lineage phenotype and drug resistance in prostate cancer | bioRxiv
- Get link
- X
- Other Apps
Serum metabolomic analysis of men on a low-carbohydrate diet for biochemically recurrent prostate cancer reveals the potential role of ketogenesis to slow tumor growth: a secondary analysis of the CAPS2 diet trial | Prostate Cancer and Prostatic Diseases
- Get link
- X
- Other Apps
Diptoindonesin G antagonizes AR signaling and enhances the efficacy of antiandrogen therapy in prostate cancer - Mao - - The Prostate - Wiley Online Library
- Get link
- X
- Other Apps
Serum metabolomic analysis of men on a low-carbohydrate diet for biochemically recurrent prostate cancer reveals the potential role of ketogenesis to slow tumor growth: a secondary analysis of the CAPS2 diet trial | Prostate Cancer and Prostatic Diseases
- Get link
- X
- Other Apps
Novartis Announces FDA Approval of Pluvicto as the First Targeted Radioligand Therapy for Advanced Prostate Cancer
- Get link
- X
- Other Apps
FDA Approves First Targeted Radioligand Therapy for Metastatic Prostate Cancer | MedPage Today
- Get link
- X
- Other Apps
Localized prostate cancer disparities in risk group at presentation and access to treatment for Hispanic men - Docwire News
- Get link
- X
- Other Apps
Androgen receptor activity in T cells limits checkpoint blockade efficacy | Nature
- Get link
- X
- Other Apps
Novartis Pluvicto™ approved by FDA as first targeted radioligand therapy for treatment of progressive, PSMA-positive metastatic castration-resistant prostate cancer
- Get link
- X
- Other Apps
Novartis Pluvicto™ approved by FDA as first targeted radioligand therapy for treatment of progressive, PSMA positive metastatic castration-resistant prostate cancer | Novartis
- Get link
- X
- Other Apps
New Trials in Prostate Cancer: Could Your Patients Benefit?
- Get link
- X
- Other Apps
ORIC Pharmaceuticals Discontinues Development of Lead Candidate Following Clinical Trial Failures
- Get link
- X
- Other Apps
Local Failure after Prostate SBRT Predominantly Occurs in the PI-RADS 4 or 5 Dominant Intraprostatic Lesion - Docwire News
- Get link
- X
- Other Apps
Comparison of Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging in Patients with Prostate Biopsy Indications - Docwire News
- Get link
- X
- Other Apps
The impact of a fasting mimicking diet on the metabolic health of a prospective cohort of patients with prostate cancer: a pilot implementation study | Prostate Cancer and Prostatic Diseases
- Get link
- X
- Other Apps
The impact of a fasting mimicking diet on the metabolic health of a prospective cohort of patients with prostate cancer: a pilot implementation study | Prostate Cancer and Prostatic Diseases : This pilot prospective study investigated the effect of a periodic fasting mimicking diet (FMD) on metabolic health factors in patients with Prostate Cancer (PC). There is a well-documented association between PC and metabolic health. Impaired metabolic health is a significant risk factor for the development of PC, and a metabolic syndrome can be induced by hormonal therapies commonly required for its management. (ClinicalTrials.gov Identifier: NCT04292041). We introduced a periodic 5-day FMD -low in calories, sugars, and proteins but high in unsaturated fats -to a cohort of PC patients and features of metabolic syndrome. 29/35 patients completed 3-monthly cycles of the 5-consecutive day packaged FMD. We compared the subjects’ baseline weight, abdominal circumference (AC), blood pressure (BP) and...
Comparison of Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging in Patients with Prostate Biopsy Indications - Docwire News
- Get link
- X
- Other Apps
Merck Halts KEYLYNK-010 Trial Evaluating Keytruda plus Lynparza for Metastatic Castration-Resistant Prostate Cancer Due to Insufficient Efficacy
- Get link
- X
- Other Apps
Local Failure after Prostate SBRT Predominantly Occurs in the PI-RADS 4 or 5 Dominant Intraprostatic Lesion - Docwire News
- Get link
- X
- Other Apps
Magnetic Seeds Used to Heat and Kill Cancer - Medical Design Briefs
- Get link
- X
- Other Apps
Node Positive Prostate Cancer – Treatment and Survival — Cancer ABCs
- Get link
- X
- Other Apps
Gene expression signature of castrate resistant prostate cancer | bioRxiv
- Get link
- X
- Other Apps
Localized prostate cancer disparities in risk group at presentation and access to treatment for Hispanic men | Prostate Cancer and Prostatic Diseases
- Get link
- X
- Other Apps
Localized prostate cancer disparities in risk group at presentation and access to treatment for Hispanic men | Prostate Cancer and Prostatic Diseases : Despite great heterogeneity amongst Hispanic groups, prostate cancer studies often report Hispanic patients in aggregate. We sought to identify differences in prostate cancer risk group at presentation and treatment status among Hispanic subgroup populations. Patients with localized prostate adenocarcinoma diagnosed from 2004–2017 were identified in the National Cancer Database (NCDB) and disaggregated by racial subgroup and Hispanic country of origin. Ordinal logistic regression defined adjusted odds ratios (AORs) with 95% CI of (1) presenting at progressively higher risk group and (2) receiving treatment with intermediate-unfavorable or high-risk disease. In our sample (n = 895,087), Hispanic men had greater odds of presenting with higher-risk localized prostate cancer compared with non-Hispanic White men (AOR = 1.18 95% CI 1.16–1...
Association of plant-based diet index with prostate cancer risk | The American Journal of Clinical Nutrition | Oxford Academic
- Get link
- X
- Other Apps
Feasibility of home-based exercise training in men with metastatic castration-resistant prostate cancer | Prostate Cancer and Prostatic Diseases
- Get link
- X
- Other Apps
[18F]-Labeled PARP-1 PET Imaging of PSMA Targeted Alpha Particle Radiotherapy Response | bioRxiv
- Get link
- X
- Other Apps
More Metastatic Prostate Cancer; How Survivors Stay Healthy; Cancer's Medical Debt | MedPage Today
- Get link
- X
- Other Apps
(1) An AI-derived digital pathology-based biomarker to predict the benefit of ADT in PC with validat... - YouTube
- Get link
- X
- Other Apps
As Use of PSA Test Fell, Rate of Advanced Prostate Cancers Rose
- Get link
- X
- Other Apps
Serum thymidine kinase 1 concentration as a predictive biomarker in prostate cancer - Lundgren - - The Prostate - Wiley Online Library
- Get link
- X
- Other Apps
Metastatic prostate cancer on the rise since decrease in cancer screenings -- ScienceDaily
- Get link
- X
- Other Apps
Prostate Cancer Patients to Reap the Benefits of “Seeds” Planted by NRG Oncology/RTOG 0526 - International Journal of Radiation Oncology, Biology, Physics
- Get link
- X
- Other Apps
Merck to stop clinical trial testing Keytruda with AstraZeneca's Lynparza in prostate cancer patients - MarketWatch
- Get link
- X
- Other Apps
Evaluation of selective bone scan staging in prostate cancer – external validation of current strategies and decision-curve analysis | Prostate Cancer and Prostatic Diseases
- Get link
- X
- Other Apps
As Predicted: Jump in Metastatic Prostate Cancer Diagnoses
- Get link
- X
- Other Apps
Which cancers are still diagnosed by standard prostate biopsy without an upfront multiparametric MRI? Results from a tertiary care, high volume centre - ScienceDirect
- Get link
- X
- Other Apps
Dosimetric benefit of MR-guided online adaptive radiotherapy in different tumor entities: liver, lung, abdominal lymph nodes, pancreas and prostate | Radiation Oncology | Full Text
- Get link
- X
- Other Apps
Assessment after focal therapy: what is the latest? : Current Opinion in Urology
- Get link
- X
- Other Apps
Implications of DNA damage repair alterations for the manage... : Current Opinion in Urology
- Get link
- X
- Other Apps
The role of novel imaging in prostate cancer focal therapy:... : Current Opinion in Urology
- Get link
- X
- Other Apps
Optimized high-throughput screening of non-coding variants identified from genome-wide association studies | bioRxiv
- Get link
- X
- Other Apps
Cancer-sniffing ants prove as accurate as dogs in detecting disease
- Get link
- X
- Other Apps
Early prostate cancers can harbor aggressive tumor cells
- Get link
- X
- Other Apps
Prostate cancer death prediction & Gleason score | CLEP
- Get link
- X
- Other Apps
SATB1, genomic instability and Gleason grading constitute a novel risk score for prostate cancer | Scientific Reports
- Get link
- X
- Other Apps
Radical Prostatectomy Without Prior Biopsy Following Multiparametric Magnetic Resonance Imaging and Prostate-specific Membrane Antigen Positron Emission Tomography - Docwire News
- Get link
- X
- Other Apps
Tumor Board Reviewing pT3N1M0 Locally Advanced Prostate Cancer - CASE 1
- Get link
- X
- Other Apps
AUA 2021: State-of-the-art Lecture: Personalized Medicine in the Management of Prostate Cancer Across the Patient Care Continuum
- Get link
- X
- Other Apps
Prostate cancer: recognition and diagnosis - The Pharmaceutical Journal
- Get link
- X
- Other Apps
Oncogenic gene fusions in nonneoplastic precursors as evidence that bacterial infection can initiate prostate cancer | PNAS
- Get link
- X
- Other Apps
Some Men With PI-RADS 5 Lesions Can Forgo Systematic Prostate Biopsy - Renal and Urology News
- Get link
- X
- Other Apps
Prostate cancer urine test identifies good prognosis patients
- Get link
- X
- Other Apps
Cureus | Gallium-68 Prostate-Specific Membrane Antigen Positron Emission Tomography: A Practical Guide for Radiologists and Clinicians
- Get link
- X
- Other Apps
Recent Advances in Systematic and Targeted Prostate Biopsies | RRU
- Get link
- X
- Other Apps
Prostate Cancer Survival Rates | Prostate Cancer Foundation
- Get link
- X
- Other Apps
The Future of Prostate Cancer Care: Taking the Fight Early
- Get link
- X
- Other Apps
Prostate cancer surgery: Types, side effects, and outlook
- Get link
- X
- Other Apps
Docetaxel in metastatic castration-resistant prostate cancer | OTT
- Get link
- X
- Other Apps
Novartis 177Lu-PSMA-617 significantly improves overall
- Get link
- X
- Other Apps
Updates in Immune Checkpoint Inhibitors for Prostate Cancer
- Get link
- X
- Other Apps
A randomized controlled trial comparing changes in fitness with or without supervised exercise in patients initiated on enzalutamide and androgen deprivation therapy for non-metastatic castration-sensitive prostate cancer (EXTEND) | Prostate Cancer and Prostatic Diseases
- Get link
- X
- Other Apps
Gleason score: What is it, results, and other measurements for prostate cancer
- Get link
- X
- Other Apps
A Decision Analysis Approach Points to Better Diagnosis of Prostate Cancer | Yale Insights
- Get link
- X
- Other Apps
Multimodality Imaging of Prostate Cancer | Journal of Nuclear Medicine
- Get link
- X
- Other Apps
Unfruitful: Eating More Produce Will Not Cure, Stop Prostate Cancer
- Get link
- X
- Other Apps
18F-DCFPyL PET/CT Imaging in Patients with Biochemically Recurrent Prostate Cancer After Primary Local Therapy | Journal of Nuclear Medicine
- Get link
- X
- Other Apps
AUA 2020: Crossfire: Controversies in Urology: Prostate Cancer Active Surveillance Can Be Done with mpMRI and Biomarkers; Biopsies are No Longer Necessary
- Get link
- X
- Other Apps
Prostate Cancer Immunotherapy Alone Is Not Enough - Renal and Urology News
- Get link
- X
- Other Apps
An Expert Discussion on Gleason 6 (Grade Group 1) Prostate Cancer - Scott Eggener
- Get link
- X
- Other Apps
Post-Operative Radiotherapy in Prostate Cancer – The State of the Data
- Get link
- X
- Other Apps
A Systematic Review of Artificial Intelligence in Prostate Cancer | RRU
- Get link
- X
- Other Apps
ASCO GU 2021: Efficacy of the PD-L1 Inhibitor Avelumab in Neuroendocrine or Aggressive Variant Prostate Cancer: Results From a Phase II, Single-Arm Study
- Get link
- X
- Other Apps
Many Cancer Centers May Not Be Following PSA Screening Advice
- Get link
- X
- Other Apps
Serendipity for the intervention of COVID-19 and prostatic adenocarcinoma (PaC) | Prostate Cancer and Prostatic Diseases
- Get link
- X
- Other Apps
Diagnostic and prognostic significance of extracellular vesicles in prostate cancer drug resistance: A systematic review of the literature | Prostate Cancer and Prostatic Diseases
- Get link
- X
- Other Apps
Quality of life after robotic‐assisted and laparoscopic radical prostatectomy: Results of a multicenter randomized controlled trial (LAP‐01) - Holze - - The Prostate - Wiley Online Library
- Get link
- X
- Other Apps
New risk algorithm would improve screening for prostate cancer -- ScienceDaily
- Get link
- X
- Other Apps
New ultrasound method as effective as MRI in diagnosing prostate cancer
- Get link
- X
- Other Apps
The role of radiotherapy in oligometastatic hormone-sensitiv... : Current Opinion in Urology
- Get link
- X
- Other Apps
Certain Types of Cancer May Increase the Risk of Developing Guillain-Barré
- Get link
- X
- Other Apps
Focal prostate cancer therapy in the era of multiparametric MRI: a review of options and outcomes | Prostate Cancer and Prostatic Diseases
- Get link
- X
- Other Apps
Liquid biomarkers for early detection of prostate cancer and summary of available data for their use in African-American men | Prostate Cancer and Prostatic Diseases
- Get link
- X
- Other Apps
Hereditary cancer risk assessment and genetic testing in the community urology practice setting - Shore - - The Prostate - Wiley Online Library
- Get link
- X
- Other Apps
(27) ESMO Expert Report on combination therapy in advanced prostate cancer @ ASCO GU 2022 - YouTube
- Get link
- X
- Other Apps
Focal prostate cancer therapy in the era of multiparametric MRI: a review of options and outcomes | Prostate Cancer and Prostatic Diseases
- Get link
- X
- Other Apps
Ultrasound scan can diagnose prostate cancer -- ScienceDaily
- Get link
- X
- Other Apps
RADAR Guide: Standard Methods for Calculating Radiation Doses for Radiopharmaceuticals, Part 2—Data Analysis and Dosimetry | Journal of Nuclear Medicine
- Get link
- X
- Other Apps
Androgen deprivation therapy for prostate cancer and the risk of thyroid diseases - Liu - - The Prostate - Wiley Online Library
- Get link
- X
- Other Apps
Survival after radical prostatectomy versus radiation therapy in clinical node‐positive prostate cancer - Chierigo - - The Prostate - Wiley Online Library
- Get link
- X
- Other Apps
Ultrasound scan can diagnose prostate cancer | EurekAlert!
- Get link
- X
- Other Apps
The History of Prostate-Specific Membrane Antigen as a Theranostic Target in Prostate Cancer: The Cornerstone Role of the Prostate Cancer Foundation | Journal of Nuclear Medicine
- Get link
- X
- Other Apps
The History of Prostate-Specific Membrane Antigen as a Theranostic Target in Prostate Cancer: The Cornerstone Role of the Prostate Cancer Foundation | Journal of Nuclear Medicine : Prostate-specific membrane antigen (PSMA) is a credentialed imaging and therapy (theranostic) target for the detection and treatment of prostate cancer. PSMA-targeted PET imaging and molecular radiotherapy are promising evolving technologies that will improve the outcomes of prostate cancer patients. In anticipation of this new era in prostate cancer theranostics, this article will review the history of PSMA from discovery through early- and late-stage clinical trials. Since 1993, the Prostate Cancer Foundation has funded critical and foundational PSMA research that established this theranostic revolution. The history and role of Prostate Cancer Foundation funding in this field will be discussed.
The Promise of Metastasis-Directed Therapy for Oligometastatic Prostate Cancer: Going Beneath the Surface with Molecular Imaging | Journal of Nuclear Medicine
- Get link
- X
- Other Apps